Asensus Surgical Announces Sale of Senhance Robotic System
November 14 2023 - 6:55AM
Asensus Surgical, Inc. (NYSE American: ASXC), a medical device
company digitizing the interface between the surgeon and the
patient, announced that a Senhance® Surgical System was sold to the
Company’s distribution partner, and will be placed in a pediatric
hospital in the Commonwealth of Independent States (CIS) region.
“We're pleased to see the increasing adoption of Senhance by
pediatric-focused hospitals. Senhance’s specialized technology such
as 3mm instrumentation, 5mm camera scope, and advanced clinical
intelligence, offers the potential to reduce invasiveness and
enhance precision, particularly in pediatric patients," noted
Anthony Fernando, President and CEO of Asensus Surgical. “We look
forward to extending these capabilities to more pediatric hospitals
and patients globally, ultimately contributing to an improved
standard of patient care.”
Caption: A Senhance Surgical System will be placed in a
pediatric hospital in the Commonwealth of Independent States (CIS)
region.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the
surgeon and patient to pioneer a new era of Performance-Guided
Surgery™ by unlocking clinical intelligence for surgeons to enable
consistently superior outcomes and a new standard of surgery. Based
upon the foundations of Digital Laparoscopy and the Senhance
Surgical System, the Company is developing the LUNA™ Surgical
System, a next generation robotic and instrument system as a
foundation of its Digital Surgery solution. These systems will be
powered by the Intelligent Surgical Unit™ to increase surgeon
control and reduce surgical variability. With the addition of
machine vision, Augmented Intelligence, and deep learning
capabilities throughout the surgical experience, we intend to
holistically address the current clinical, cognitive and economic
shortcomings that drive surgical outcomes and value-based
healthcare. The Senhance Surgical System is now available for sale
in the US, EU, Japan, Russia, and select other countries. For a
complete list of indications for use, visit:
www.senhance.com/indications. To learn more about
Performance-Guided Surgery, and digital laparoscopy with the
Senhance Surgical System visit www.asensus.com.
Follow Asensus
Email Alerts: https://ir.asensus.com/email-alerts
LinkedIn:
https://www.linkedin.com/company/asensus-surgical-inc
Twitter: https://twitter.com/AsensusSurgical
YouTube: https://www.youtube.com/@AsensusSurgical
Vimeo: https://vimeo.com/asxc
TikTok: https://www.tiktok.com/@asensus_surgical
Forward-Looking Statements
This press release includes statements relating to the Senhance
Surgical System and the sales of a Senhance System to be placed in
a hospital in the Commonwealth of Independent States. These
statements and other statements regarding our future plans and
goals constitute "forward looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, and are intended to qualify for
the safe harbor from liability established by the Private
Securities Litigation Reform Act of 1995. Such statements are
subject to risks and uncertainties that are often difficult to
predict, are beyond our control and which may cause results to
differ materially from expectations and include whether we will be
able to extend the Senhance System’s specialized technology to more
pediatric hospitals and patients globally, ultimately contributing
to an improved standard of patient care. For a discussion of the
risks and uncertainties associated with the Company’s business,
please review our filings with the Securities and Exchange
Commission (SEC), including our Annual Report on Form 10-K for the
year ended December 31, 2022, filed with the SEC on March 2, 2023
and our other filings we make with the SEC. You are cautioned not
to place undue reliance on these forward looking statements, which
are based on our expectations as of the date of this press release
and speak only as of the origination date of this press release. We
undertake no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise.
INVESTOR CONTACT:
Mark Klausner or Mike Vallie, 443-213-0499
invest@asensus.com
MEDIA CONTACT:
Dan Ventresca
Matter Communications
AsensusPR@matternow.com
617-874-5488
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/e76f446f-e028-499f-ba7a-3ae25c9369c9
Asensus Surgical (AMEX:ASXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Asensus Surgical (AMEX:ASXC)
Historical Stock Chart
From Apr 2023 to Apr 2024